[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1997008309A3 - Ribozyme therapy for hepatitis b infections - Google Patents

Ribozyme therapy for hepatitis b infections Download PDF

Info

Publication number
WO1997008309A3
WO1997008309A3 PCT/US1996/013975 US9613975W WO9708309A3 WO 1997008309 A3 WO1997008309 A3 WO 1997008309A3 US 9613975 W US9613975 W US 9613975W WO 9708309 A3 WO9708309 A3 WO 9708309A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
infections
hbv
infection
methods
Prior art date
Application number
PCT/US1996/013975
Other languages
French (fr)
Other versions
WO1997008309A2 (en
WO1997008309A9 (en
Inventor
Tsvi Goldenberg
Mang Yu
Peter J Welch
Jack R Barber
Original Assignee
Immusol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immusol Inc filed Critical Immusol Inc
Publication of WO1997008309A2 publication Critical patent/WO1997008309A2/en
Publication of WO1997008309A3 publication Critical patent/WO1997008309A3/en
Publication of WO1997008309A9 publication Critical patent/WO1997008309A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides ribozymes useful to treat or prevent Hepatitis B Virus ('HBV') infection in an organism or subject, as well as methods of treating an HBV infection. Reagents such as vectors, host cells, DNA molecules coding for these ribozymes useful in methods of treatment and prevention of HBV infection also are provided.
PCT/US1996/013975 1995-08-29 1996-08-29 Ribozyme therapy for hepatitis b infections WO1997008309A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52125595A 1995-08-29 1995-08-29
US08/521,255 1995-08-29

Publications (3)

Publication Number Publication Date
WO1997008309A2 WO1997008309A2 (en) 1997-03-06
WO1997008309A3 true WO1997008309A3 (en) 1997-07-10
WO1997008309A9 WO1997008309A9 (en) 1997-08-14

Family

ID=24076029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/013975 WO1997008309A2 (en) 1995-08-29 1996-08-29 Ribozyme therapy for hepatitis b infections

Country Status (1)

Country Link
WO (1) WO1997008309A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0522578D0 (en) * 2005-11-04 2005-12-14 King S College London Ribozymal nucleic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304578A1 (en) * 1987-06-22 1989-03-01 Medeva Holdings B.V. Peptide comprising hepatitis B surface antigen
WO1995022600A1 (en) * 1994-02-22 1995-08-24 Immusol, Inc. Ribozyme therapy for hepatitis b infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0304578A1 (en) * 1987-06-22 1989-03-01 Medeva Holdings B.V. Peptide comprising hepatitis B surface antigen
WO1995022600A1 (en) * 1994-02-22 1995-08-24 Immusol, Inc. Ribozyme therapy for hepatitis b infection

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BECK, J. AND NASSAL, M.: "Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal in vitro and in cell extracts, but not in intact cells", NUCLEIC ACIDS RESEARCH, vol. 23, no. 24, 1995, pages 4954 - 4962, XP002029174 *
GEORG, S.T. ET AL.: "Ribozyme-mediated cleavage of hepatitis B virus surface antigen mRNA", ANTIVIRAL RESEARCH, vol. 20, no. supp.1, 1993, pages 165, XP000652951 *
KIJIMA, H. ET AL.: "Therapeutic applications of ribozymes", PHARMACEUTICAL THER., vol. 68, no. 2, 1995, pages 247 - 267, XP000612090 *
WANG, P. ET AL.: "Effects of ribozyme on HBV in vitro and in HepG2 cell", FASEB JOURNAL, vol. 7, no. 7, 1993, pages a1301, XP002029175 *
YU, M. ET AL.: "In vitro and in vivo characterization of a second functional hairpin ribozyme against HIV-1", VIROLOGY, vol. 206, 1995, pages 381-386, XP000652043 *

Also Published As

Publication number Publication date
WO1997008309A2 (en) 1997-03-06

Similar Documents

Publication Publication Date Title
WO1997032018A3 (en) Hepatitis c virus ribozymes
WO2003044053A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
WO2003008443A3 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2210353A1 (en) Stabilized external guide sequences
ATE464391T1 (en) HYALURONIDASE FROM HUMAN PLASMA
IL123467A0 (en) Methods and compositions for the selective modification of nucleic acids
WO2004039829A3 (en) Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
AU1664695A (en) Process for producing endotoxin-free or endotoxin-poor nucleic acids and/or oligonucleotides for gene therapy
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
FR2711670B1 (en) Nucleotide vector, composition containing it and vaccine for immunization against hepatitis.
AU4992985A (en) Method and system for removing immunosuppressive components from the blood of mammals
BR9204699A (en) COMPOUNDS CONTAINING IMIDAZOLINONE OR IMIDAZOLINTIONA GROUP, PROCESSES OF PREPARATIONS OF THESE COMPOUNDS, FUNGICIDED COMPOSITES AND CULTURE TREATMENT PROCESS
WO2002097030A3 (en) Peptides derived from neural thread proteins and their medical use
WO2003039458A3 (en) TREATMENT OF HUMAN CANCER WITH ADENOVIRAL VECTOR EXPRESSING TNF-α
EP1857115A3 (en) Using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
WO2002006513A3 (en) A method for treating herpes viruses
DE69834724D1 (en) Treatment of bowel or bladder infections
CA2109977A1 (en) Giardia vaccines
WO1997008309A3 (en) Ribozyme therapy for hepatitis b infections
CA2245545A1 (en) Vaccines against varicella zoster virus gene 63 product
CA2138793A1 (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
EP0552257A4 (en) A plant protein useful for treating tumors and hiv infection
EP1549672A4 (en) REDUCTION OF CELL PENETRATION DEPENDENT OF LYMPHOCYTIC ACTIVATION MOLECULE (SLAM)
FI965114A7 (en) Pharmaceutical composition for the prevention and (or) treatment of viral infections and optionally inflammations, and method of treating them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6,DRAWINGS,REPLACED BY NEW PAGES 1/8-8/8;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase